Clinical Trials

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07527806 2026-04-17

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

156 enrolled

Breast Neoplasms

NCT05879926 2026-04-02

OFSET

Phase 3 Recruiting

3,960 enrolled

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

263 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07423611 2026-02-20

RACE

388 enrolled

Breast Neoplasms

NCT06970912 2026-01-21

DNADalHR

393 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT02760030 2025-12-19

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

14 enrolled

Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

144 enrolled

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

Phase 3 Completed

1,017 enrolled

Breast Neoplasms

NCT06361940 2025-10-14

MAPPER

100 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

77 enrolled

Breast Neoplasms

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

18 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06996093 2025-05-30

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

2,508 enrolled

Breast Neoplasms

NCT05362760 2025-05-16

MINERVA

Phase 4 Recruiting

300 enrolled

Breast Neoplasms

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Breast Neoplasms

NCT03944434 2025-02-26

FACILE

116 enrolled

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Breast Neoplasms

NCT02188745 2024-07-17

POLLY

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04240106 2024-02-16

LUZERN

14 enrolled

Breast Neoplasms

NCT05949541 2024-02-08

BCTOP-L-M01

265 enrolled

Breast Neoplasms

NCT00499083 2023-09-29

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

17 enrolled 5 charts

Breast Neoplasms

NCT02914158 2023-01-17

ASPAIT

Phase 3 Unknown

680 enrolled

Breast Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

181 enrolled

Breast Neoplasms

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Phase 1 Withdrawn

Breast Neoplasms

NCT01950182 2020-07-15

SYSUCC-002

Phase 3 Completed

392 enrolled

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

10 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT02338310 2020-02-17

POETIC

4,486 enrolled

Breast Neoplasms

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

77 enrolled

Breast Diseases, Breast Neoplasms

NCT04012918 2019-07-09

CONCEPT

124 enrolled

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

250 enrolled

Breast Diseases, Breast Neoplasms

NCT00111241 2018-12-14

Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors

Completed

115 enrolled 6 charts

Breast Neoplasms, Osteoporosis, Arthralgia, Fractures, Bone

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

Breast Neoplasms

NCT02769104 2018-01-09

ACCN

Phase 3 Unknown

120 enrolled

Breast Neoplasms

NCT02910050 2017-12-22

BETTER

58 enrolled

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT00755313 2017-11-24

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

Completed

81 enrolled

Breast Neoplasms, Fatigue, Neurotoxicity Syndromes

NCT01654185 2017-03-14

Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer

60 enrolled

Breast Neoplasms

NCT01298362 2016-09-20

POCHARBI

Completed

290 enrolled 19 charts

Breast Neoplasms

NCT01293032 2016-07-12

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Phase NA Completed

59 enrolled 11 charts

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02394496 2016-06-15

OVER

Phase 3 Unknown

396 enrolled

Breast Neoplasms

NCT01814865 2013-12-20

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT01924078 2013-08-16

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

100 enrolled

Breast Neoplasms

NCT01612728 2013-02-12

AIA

Phase 2 Withdrawn

Breast Neoplasms, Arthralgia

NCT00766532 2012-09-14

Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?

Phase 4 Completed

12 enrolled 5 charts

Bone Diseases, Metabolic, Breast Neoplasms, Osteoporosis, Fractures, Bone

NCT01654367 2012-07-31

esozao

Phase 2/3 Unknown

300 enrolled

Breast Neoplasms

NCT00935558 2012-05-31

Dendritic Cell Based Therapy for Breast Cancer Patients

Phase 2 Withdrawn